Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

Table 4 Model inputs: probabilities of hospitalization for heart failure and death for dapagliflozin/DPP-4i treated patients

Patient groups	Base analysis		Sensitivity analysis
Patient groups	Dapagliflozin	DPP-4i	Dapagliflozin	DPP-4i
All patients
hHF incidence	0.0054	0.0078	0.0040	0.0068
HF death	0.0198	0.0253	0.0198	0.0253
Other death	0.0010	0.0013	0.0010	0.0013
Patients with underlying CVD
hHF incidence	0.0145	0.0220	0.0113	0.0205
HF death	0.0105	0.0243	0.0105	0.0243
Other death	0.0016	0.0024	0.0016	0.0024
Patients without underlying CVD
hHF incidence	0.0036	0.0048	0.0025	0.0038
HF death	0.0355	0.0264	0.0355	0.0264
Other death	0.0009	0.0010	0.0009	0.0010

Data source: Claim data of the Health Insurance Review & Assessment services
DPP-4i Dipeptidyl-peptidase 4 inhibitor, hHF hospitalization for heart failure, HF heart failure, CVD cardiovascular disease

ISSN: 1475-2840